Provider-Guided Assessment: Who Should Consider Semaglutide and Why Semaglutide is most appropriate for adults with BMI 30 kg/m (or 27 with weight-related comorbidities like hypertension or type 2 diabetes) who have failed lifestyle modification alone
Record the Injection: Keep a record of the date, time, and location of each injection, as advised by your healthcare provider
Last reviewed: April 21, 2026 Updated with Phase 3 TRIUMPH-4 data Primary sources: NEJM, Eli Lilly, ClinicalTrials.gov Retatrutide is a triple agonist (GLP-1 + GIP + glucagon) currently in Phase 3 trials, showing stronger early weight loss data
This systematic review aims to critically assess the mechanisms of action, usage trends, efficacy, and safety profiles of DHA-based products, synthetic melanocortin analogs, and less conventional agents such as forskolin and carotenoids
The same applies if you experience severe chest pain or severe breathlessness